MiMedx price target raised to $9.50 from $8 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on MiMedx to $9.50 from $8 and keeps a Buy rating on the shares post the Q1 results. The company reported cash and cash equivalents of $61.2M which is sufficient to fund operations for the foreseeable future, the analyst tells investors in a research note. The firm views the Q1 results as "strong."